ScreenerHero

HAE Haemonetics Corporation

NYSE · US · Healthcare · Medical Devices · haemonetics.com
104.68USD0.00%Mkt Cap: 4.76B $P/E: 50.57

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collectio…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$174.36BUSDP/E 32.3
MDT
Medtronic plc
$112.53BUSDP/E 21.6
SYK
Stryker Corporation
$109.40BUSDP/E 29.6
BSX
Boston Scientific Corporation
$61.45BUSDP/E 17.2
EW
Edwards Lifesciences Corporation
$50.23BUSDP/E 51.9
SHL
Siemens Healthineers AG
$46.06BUSDP/E 19.2
DXCM
DexCom, Inc. - Common Stock
$32.21BUSDP/E 33.7
GEHC
GE HealthCare Technologies Inc. - Common Stock
$29.24BUSDP/E 14.8
PHG
Koninklijke Philips N.V.
$23.37BUSDP/E 17.8
PHIA
Koninklijke Philips N.V.
$22.58BUSDP/E 18.5
STE
STERIS plc
$20.58BUSDP/E 25.8
SOON
Sonova Holding AG
$17.06BUSDP/E 27.9
ZBH
Zimmer Biomet Holdings, Inc.
$17.47BUSDP/E 22.2
PEN
Penumbra, Inc.
$12.49BUSDP/E 77.9
TXG
10x Genomics, Inc. - Common Stock
$12.18BUSD
SNN
Smith & Nephew plc
$11.27BUSDP/E 18.3
GMED
Globus Medical, Inc.
$10.28BUSDP/E 19.6
BIO
Bio-Rad Laboratories, Inc.
$10.16BUSDP/E 48.1
DEMANT
Demant A/S
$9.81BUSDP/E 27.8
GKOS
Glaukos Corporation
$9.67BUSD

Key Statistics

Company
Market Cap4.76B USD
Enterprise Value5.71B USD
Revenue (TTM)1.35B USD
Gross Profit787.59M USD
Net Income (TTM)97.31M USD
Revenue/Share29.08 USD
Last Price104.68 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees3.0K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)50.57
P/E (Forward)18.12
PEG1.66
EV/EBITDA15.92
EV/Revenue4.23
P/S3.52
P/B5.69
EPS (TTM)2.07
EPS (Forward)5.78
52W Range
47.7291% of range110.45
52W High110.45 USD
52W Low47.72 USD
Profitability
Gross Margin59.04%
Oper. Margin17.93%
EBITDA Margin26.54%
Profit Margin7.29%
ROE12.22%
ROA4.06%
Growth
Revenue Growth5.60%
Earnings Growth2.90%
Cash Flow & Leverage
Operating CF293.22M USD
CapEx (TTM)32.78M USD
FCF Margin23.14%
FCF Yield6.57%
Net Debt949.64M USD
Net Debt/EBITDA2.65
Balance Sheet
Debt/Equity1.54
Current Ratio3.08
Quick Ratio1.67
Book Value/Sh18.41 USD
Cash/Share4.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateDec 3, 2012
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)111.50 USD
Upside (mean)+6.5%
Target Range86.00 USD – 125.00 USD
86.00+6.5% to mean125.00
# Analysts10
Ownership
Shares Out.45.50M
Float44.89M
Insiders1.26%
Institutions112.44%
Short Interest
Short Ratio4.7d
Short % Float8.81%
Short % Out.7.53%
Shares Short3.42M
Short (prev mo.)2.76M
Technical
SMA 5098.88 (+5.9%)
SMA 20075.02 (+39.5%)
Beta0.54
S&P 52W Chg14.58%
Avg Vol (30d)568.25K
Avg Vol (10d)460.30K
Technical Indicators
RSI (14)55.4
MACD1.9014
MACD Signal2.8080
MACD Hist.-0.9066
BB Upper109.67 USD
BB Middle105.44 USD
BB Lower101.21 USD
BB Width8.02%
ATR (14)2.562 USD
Vol Ratio (20d)0.58x